Skip to content

Up-regulation of semicarbazide-sensitive oxidase (hSSAO) is a key cause of vascular dementia

Up-regulation of semicarbazide-sensitive oxidase (hSSAO) is a key cause of vascular dementia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900026397
Enrollment
Unknown
Registered
2019-10-08
Start date
2018-01-01
Completion date
Unknown
Last updated
2019-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vascular dementia

Interventions

Hemorrhage group:None
Control group:None

Sponsors

China Rehabilitation Research Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Criteria for clinically likely vascular dementia that meet the NINDS-AIREN diagnostic criteria: (1) dementia: Clinical presentation: cognitive function is reduced compared with the past, manifested as functional impairment (directionality, attention, language, visual function, executive function, motor function and implementation function) in the cognitive field of memory impairment level; Neuropsychological test: MMSE =7 points; 3. cognitive impairment has a causal relationship with vascular factors; 4. the presence of hyperlipidemia; 5. There is atherosclerotic plaque in carotid ultrasound; 6. Informed consent and independent completion of neuropsychological assessment.

Exclusion criteria

Exclusion criteria: (1) Neurodegenerative cognitive disorders (Alzheimer's disease, frontotemporal dementia, Lewy body dementia, Parkinson's disease dementia, etc.); (2) Cognitive impairment caused by inflammatory and infectious diseases (CJD, AIDS, syphilis, etc.); (3) normal intracranial pressure hydrocephalus, brain tumor, brain trauma, demyelinating diseases of the nervous system; (4) Cognitive impairment caused by systemic diseases (hypothyroidism, vitamin deficiency, etc.); (5) Toxic cognitive impairment (alcoholism, chronic poisoning, etc.); (6) severe dementia (CDR = 3); (7) Depression and other psychiatric symptoms; (8) Those with severe liver and kidney damage.

Design outcomes

Primary

MeasureTime frame
MiR-134;AOPC3 (ug/µL);SSAO (ng/mL);H2O2 (uM);FA (uM);FA (uM);FC (ug/mL);

Countries

China

Contacts

Public ContactYan Yu

China Rehabilitation Research Center

yuyancrrc@163.com+86 13426262203

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026